DigiTx Partners

We’re thrilled to announce that Tali AI has been selected as a pre-qualified vendor for Canada Health Infoway AI Scribe Program, a national initiative designed to modernize documentation and reduce administrative burden for primary care clinicians across Canada. Through this program, up to 10,000 fully funded, one-year licenses will be made available to: ✅ Family physicians ✅ Nurse practitioners ✅ Registered nurses in remote communities ✅ Pediatricians providing longitudinal, community-based care Tali is a Canadian-built AI medical scribe designed to: • Streamline clinical workflows • Save time on documentation • Integrate with 70% of Canadian EMRs • Meet national privacy and data standards We’re proud to be selected through a rigorous national review process for our commitment to privacy, usability, and interoperability. The program officially opens to clinicians next week, and early interest is already high. To learn more, access resources, and register your interest: 👉 https://lnkd.in/efpTMRa8 Find out more about Tali 👉 https://tali.ai/infoway #TaliAI #AIScribe #Infoway #DigitalHealth #HealthInnovation #PrimaryCare #CanadianHealthTech #ClinicianSupport

🌟 Exciting News! Welldoc® is powering the newly launched Lilly Health™ Personalized Health & Medicine Platform* (Lilly Health app) for individuals interested in or using Lilly's incretin-based therapies, for the treatment of cardiometabolic conditions, like obesity, type 2 diabetes, and moderate-to-severe obstructive sleep apnea and obesity.     Learn more in the press release: https://ter.li/r0j3lm #Welldoc #digitalhealth #AI

We are so proud to announce our Seed financing round today! It has been an incredible journey working with our partners, providing the much needed care to their patients, and building up an amazing team and culture here at #CerulaCare. We are so excited for this next chapter of growth. There would be no raise if it weren't for the amazing team here at Cerula and the incredible investors who are trusting us and supporting us on this journey; #grateful is truly an understatement for how we feel right now. Thank you so very much - this is going to be an amazing, impactful journey together for all of us, for our oncology providers, and most importantly for our members. Shout out to our Seed round investors: Esplanade Ventures (Ella Seitz, Dr. Sheldon Elman) who led this round, Amplify Capital, BrightEdge - American Cancer Society ,DigiTx Partners, SpringTime Ventures, and Mike Pykosz (former CEO and co-founder of Oak Street Health). And, we had such an amazing group of Pre-Seed angel investors who believed in us from the very beginning, alongside Flare Capital Partners (Ian Chiang Jonathon George), One Mind, Healthworx. See the full story here: https://lnkd.in/ei2Uc9zp And, big thank you to Ngai Yeung at Endpoints News for featuring us! https://lnkd.in/ejV4K3Up

Cleveland Clinic is transforming how we care for patients with disorders of gut-brain interaction (DGBI), like irritable bowel syndrome (IBS) and functional constipation, through a partnership with Ayble Health. By leveraging Ayble’s AI-enabled digital care platform, patients now have access to behavioral health resources and personalized nutrition support—all from the convenience of an app. What makes this platform game-changing? - Combines mental health tools (mindfulness, meditation, etc.) with AI-powered symptom tracking. - Offers nutrition guidance tailored to individual needs, helping identify and manage food triggers. - Provides 24/7 access to a multidisciplinary virtual care team, including health coaches and Cleveland Clinic providers. DGBI affects 4 in 10 U.S. adults and can severely impact quality of life. By addressing both the physical and psychological aspects of these conditions, Cleveland Clinic is delivering whole-person care, improving outcomes, and alleviating provider shortages in GI care. This innovative collaboration ensures seamless integration between digital and in-person care, giving patients the support they need, when and where they need it. Cleveland Clinic and Ayble Health co-developed care pathways and behavioral health content that is now available on the virtual care platform. Learn more about how digital health is reshaping the future of GI care. https://hubs.li/Q033QltT0 #HealthcareInnovation #DigitalHealth #DigestiveHealth #AIHealthcare #ClevelandClinic #PatientCare

Embr Labs Awarded Six Patents for AI-Driven Digital Therapeutics! This milestone is a testament to the innovation and dedication of our team. My co-founder, Matthew Smith, has been leading Embr's Intellectual Property development from day one. When we drafted our first provisional patent back in October 2013, I didn’t realize how much of a marathon (or maybe an ultra-marathon!) the patent process would be. But Matt’s long-term vision, persistence, and unwavering commitment have been instrumental in advancing and protecting Embr’s groundbreaking technology. These six patents reflect our mission to push the boundaries of AI-driven thermal wellness and deliver real impact for our customers. Here’s to more innovation ahead! Read more about this exciting milestone here: https://lnkd.in/gMaB6XuB

We are pleased to announce that we have listed our new #DigitalHealth solution for the management of #HeartFailure with the U.S. Food and Drug Administration (FDA).  Heart failure is a global health issue affecting more than 64 million people worldwide. In the U.S., the prevalence of heart failure is 6.9 million (2020 estimate) and is expected to increase by 24% to nearly 8.5 million by 2030 due to the aging and growth of the U.S. population. This milestone represents an important step forward in helping patients impacted by heart failure take a more active role in managing their health. We are proud to offer a non-invasive digital health option that enables at-home disease monitoring and physician intervention when necessary.    Read more here:  https://lnkd.in/gX7zgZVT

Eko Health's AI 𝗱𝗼𝘂𝗯𝗹𝗲𝗱 𝘁𝗵𝗲 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗵𝗲𝗮𝗿𝘁 𝗳𝗮𝗶𝗹𝘂𝗿𝗲 𝗶𝗻 𝗽𝗿𝗲𝗴𝗻𝗮𝗻𝘁 𝘄𝗼𝗺𝗲𝗻 in a recent randomized controlled clinical trial published in Nature Medicine. Led by Dr. Demilade Adedinsewo at Mayo Clinic, the trial evaluated the performance of Eko’s recently FDA-cleared Low EF AI technology in detecting ejection fraction (EF) at several thresholds, a key metric of heart pump function typically captured using cardiac ultrasound. Involving over 1,200 participants, the study demonstrated that Eko’s Low EF AI technology enabled healthcare professionals to detect PPCM at twice the rate of traditional obstetric care. “This study represents a significant step forward in using AI to address critical healthcare challenges, particularly in underserved regions where maternal health outcomes are most at risk,” said Connor Landgraf, CEO and co-founder of Eko Health. “Our mission at Eko has always been to bridge the gap in cardiovascular care access through innovative technology. The results of this trial reinforce our commitment to providing accessible, life-saving tools to healthcare providers around the world, enabling them to detect heart disease earlier and improve patient outcomes.” Learn more: https://lnkd.in/gJB7NSxZ